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METHOD FOR ENHANCING PROTECTIVE 
CELLULAR RESPONSES TO GENOTOXIC 
STRESS IN SKIN 
CROSS REFERENCE TO RELATED 
APPLICATIONS 
This application claims bene?t of provisional patent 
application serial No. 60/110,482 ?led Dec. 1, 1998. The 
entire disclosure of provisional patent application serial No. 
60/110,482 is hereby incorporated by reference. 
BACKGROUND 
1. Field of the Invention 
The invention is directed to methods and composition of 
using organic molecules termed pro-NAD agents capable of 
enhancing dermal and epidermal skin cell NAD content With 
a resulting enhancement of DNA repair and other protective 
responses to genotoxic stress in skin. 
2. Description of the Background 
The present application relates to methods and composi 
tions capable of modulating and upregulating the cellular 
nicotinamide-adenine-dinucleotide (NAD) content by the 
topical application of chemical agents for the purpose of 
enhancing natural protective responses of skin cells to DNA 
damage. The methods and compositions are effective for the 
prevention and treatment of skin deterioration that results 
from DNA damage to cells of the skin. The symptoms of 
such skin deterioration are many and typically include the 
loss of moisture, ?ne lines, deep lines, Wrinkles, and loss of 
elasticity as Well as atrophic sclerosis and other blemishes of 
skin. Skin deteriorates With age as a natural consequence of 
prolonged exposure to internal and external factors. Internal 
deterioration factors include natural metabolic byproducts 
such as free radicals Which cause the aging of all tissues. 
External deterioration factors include ioniZing radiation 
such as sunlight and chemical insults such as pollution and 
cigarette smoke. In theory, skin care methods and compo 
sitions should inhibit, or sloW the process of skin deterio 
ration by counteracting these internal and external factors. 
Unfortunately, current methods and compositions for skin 
care are generally reactive rather than proactive. That is, 
current methods and compositions reduce or obscure the 
signs of aging but have minimal or no effect on the under 
lying progressive and cumulative biochemical processes that 
cause skin deterioration. It is therefore desirable to have a 
skin care method and composition Which not only reduce the 
symptoms of deterioration but also treat the underlying 
causes of skin deterioration in such a Way that deterioration 
can actually be retarded. To understand the limitations of 
current methods and compositions, it is necessary to under 
stand the function and structure of the skin and the mecha 
nisms of skin deterioration. 
At ten pounds, the skin is the largest organ in the body. 
FIG. 1 shoWs a diagram of skin marking the location of the 
tWo major cell types present in skin, namely ?broblasts 
located in the dermal layer of the skin and keratinocytes 
located in the epidermal layer of the skin. The skin provides 
the ?rst line of defense betWeen the body’s interior and 
harmful environmental insults by Well established physical 
and biochemical mechanisms. Physical protection mecha 
nisms include the relatively impermeable barrier the skin 
provides. The skin can, to some extent, repel and absorb 
insults such as chemicals and ultraviolet light so that While 
the skin maybe damaged, the underlying tissue is preserved. 
Biochemical mechanisms include the innate and acquired 
immune systems. Microbiological pathogens are repelled by 
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immune responses at the epidermal level involving Langer 
hans cells, keratinocytes, cytokines, polynuclear cells, 
endothelial cells, mast cells, and lymphocytes. 
Structurally, the skin comprises epithelial tissue (the 
epidermis) in the outer layer and beneath it, connective 
tissue (the dermis), and beneath that, the fatty tissue 
(hypodermis). The epidermis is not vasculariZed and regen 
erates every four to six Weeks. Its primary function is to 
maintain the body’s skin integrity, acting as a physical 
barrier to toxic agents, dirt, bacteria, microorganisms, and 
physical insults. The dermis is beneath the epidermis and 
functions by providing strength, support, blood, and oxygen 
to the skin. The principal cell components of the dermis are 
?broblasts although it also contains sWeat glands, sebaceous 
glands, hair follicles, and small fat cells. Hypodermis, also 
knoWn as the super?cial fascia, attaches the dermis to the 
underlaying structures. Its function is to promote an ongoing 
blood supply to the dermis for regeneration. 
The mechanisms of skin deterioration involve a gradual 
and progressive process that begins from birth. Internal 
factors that contribute to skin aging include toxic metabolic 
byproducts, autoimmune diseases, and genetic predisposi 
tion. The consequences of internal deterioration can be 
observed over the entire body from the skin to the internal 
organs. While the mechanisms of internal deterioration are 
not completely understood, somatic mutation has been 
shoWn to be a contributing factor. Under the somatic muta 
tion theory, cells gradually lose their youthful characteristics 
and their capacity to divide by the accumulation of muta 
tions (errors) in their genetic code. These mutations may be 
caused by free radicals or alkylating agents generated in 
metabolism that lead to unrepaired DNA damage. Over time, 
mutations accumulate in the body until the cell can no longer 
divide or produce functional proteins. 
External factors such as chemical and physical agents in 
the environment can also cause DNA damage that leads to 
skin deterioration. The external factors include sunlight, 
pollution, and ingested chemicals from smoking or from 
food. 
Deterioration of skin leads to changes in dermal thickness 
and elasticity due to increased crosslinking of collagen. 
Epidermal regeneration increases in activity While 
metabolism, sWeat glands, and vasculariZation, all decrease 
in activity. The damage from internal and external factors is 
progressive and cumulative and results in the appearance of 
deterioration associated With aged skin. 
Related to the somatic mutation theory, both internal and 
external factors contribute to oxidative stress, Which in turn 
results in DNA damage. In humans, oxidative stress and 
DNA damage is caused by factors such as hyperbaric 
oxygen, gamma radiation, ultraviolet radiation, oZone, 
peroxides, free radicals, alkylating agents, and redox cycling 
drugs. While total oxidative stress and DNA damage may be 
reduced by living in a loW pollution environment and 
avoiding sunlight, they cannot be eliminated. Some factors 
like ioniZing radiation are present in all environments at a 
loW level and other factors are byproducts of metabolism 
and cannot be totally eliminated. Further, urban environ 
ments have high levels of ground level pollution from a 
variety of sources that are not likely to be reduced in the near 
future. HoWever, While DNA damage cannot be avoided, not 
all DNA damage leads to mutations. 
DNA damage does not necessarily lead to mutation 
because a normal cell contains diverse and effective systems 
for repairing damaged DNA. There are at least 50, and 
possibly more than 100 genes involved in DNA repair. The 
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importance of good DNA repair in retarding skin deteriora 
tion is most noticeable in patients that suffer from DNA 
repair defects such as xeroderma pigmentosum XP 
have early and accelerated skin deterioration, clearly dem 
onstrating the importance of DNA repair to reducing dete 
rioration of the skin. In addition to DNA repair, a normal cell 
also has systems that invoke “programmed cell death” by a 
process termed apoptosis. The process of apoptosis effec 
tively “erases” cells damaged beyond the point of repair. 
These natural defense mechanisms of the skin have been 
ignored by current methods of preventing skin deterioration. 
Many creams, lotions, bath oils, ointments, pastes, 
cleansers, covers, and poWders claim to be effective in 
preventing skin deterioration. HoWever, all current methods 
and compositions have severe disadvantages in that they are 
limited in their ability to retard skin deterioration. Most over 
the counter skin care products soften deteriorated skin or 
otherWise reduce the symptoms of deteriorated skin With no 
effect on the underlying biochemical processes involved in 
deterioration. Many existing skin care products and cosmet 
ics function by providing moisture to the skin, preventing 
moisture loss, or providing cover to obscure the visible signs 
of deterioration. While traditional cosmetics may have 
effects on appearance, these effects are evanescent and any 
apparent improvement disappears as soon as the product use 
is discontinued. Further, traditional cosmetics’ effectiveness 
decrease upon exposure to moisture and thus cosmetics must 
be reapplied after exercise, sWimming, or any other expo 
sure to moisture. Some cosmetics contain metals (e.g., iron 
and copper) Which may actually increase skin levels of free 
radical formation and possibly promote deterioration. As the 
use of such products does not prevent deterioration, more 
and more of the product is needed as time progresses to 
obscure the increasing severe condition of the underlying 
skin. 
Another method for treating aging skin is the use of alpha 
hydroxy acids (AHA) such as lactic acid, citric acid, glycolic 
acid, malic acids; beta hydroxy acids (BHA) such as sali 
cylic acid; and retinoids (e.g. tretinoin (retin A), retinol and 
retinal), as exfoliants. These agents help remove the upper 
most layer of skin to expose the more youthful underlying 
skin. HoWever, there is a danger that by removing the outer 
layer of skin, AHA, BHA and retinoids can compromise the 
important barrier function of skin. It is possible that the use 
of these exfoliants may accelerate skin aging by removing 
the protective outer layer of skin. Exfoliants and other 
ingredients may also increase the skin’s sensitivity to envi 
ronmental conditions such as sunlight, Wind, cold tempera 
ture and dry air, or to chemical agents such as antigens, or 
may exacerbate the irritation attributable to a pre-existing 
skin disease. Another disadvantage of AHA, BHA and 
retinoids is that these compounds are potential skin irritants 
Which can induce side effects such as sore, red skin. 
Another popular method for skin treatment is the use of 
sunblocks. Sunblock (i.e., sunscreen) refers to any chemical 
that When applied to the skin, reduces the amount of UV 
light that reaches the skin. By preventing UV absorptions 
that cause genomic mutations, sunblocks can decrease and 
retard skin deterioration. Sunblocks Were originally 
designed to prevent sunburn (also knoWn as erythema), an 
acute reaction to overexposure to the sun. The strength of 
sunblocks is measured by the SPF index (Sun Protection 
Factor). An SPF value of 15, for example, Will provide 15 
times the protection of bare skin to sunburns. HoWever, it 
should be noted that the SPF values, Which measures resis 
tance to sunburn, cannot be extrapolated to photoaging 
protection, Which is caused by constant loW level environ 
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mental insults. That is, a sunblock With an SPF factor of 15 
Will not reduce photoaging 15 fold. There is also a danger 
that chemicals in some sunblocks Will increase DNA dam 
age and contribute to skin deterioration. Finally, every major 
class of sunblock has been linked to skin allergies. 
Finally, there are agents that are physical blends of 
existing agents. Aphysical blend is a mixture of tWo or more 
chemicals. Physical blends can be mixed poWders, mixed 
solutions, mixed emulsions, mixed colloidal solutions, par 
ticles in solutions, and the like. An example of a physical 
blend may be a covering or coloring cosmetic mixed With a 
sunblock (titanium dioxide) and a hydroxy acid. 
In summary, current methods of skin treatment are mostly 
reactive in that they treat the symptoms of deterioration after 
the damage is done. Current skin treatment methods do not 
reverse damage to the dermal tissue. There is a need for 
topical skin care products that are proactive rather than 
reactive. A proactive product is one that Will assist the skin 
in resisting DNA damage by either preventing damage or 
assisting in repair of any damage. 
SUMMARY OF THE INVENTION 
The present invention overcomes many of the limitations, 
problems and disadvantages associated With current strate 
gies and designs for preventing skin deterioration and pro 
vides methods and composition for the treatment of skin 
deterioration. 
One object of the invention is directed to a method and 
composition for treating skin to prevent and sloW the dete 
rioration process. 
It is another objective of the invention to provide a 
method to retard deterioration of the skin by enhancing the 
skin’s natural DNA repair mechanism. 
It is another object of the invention to provide a method 
for the sustained release of pro-NAD agents to skin cells. 
Another object of the invention is directed to a compo 
sition for topical application comprising one or more pro 
NAD agent that promote cellular DNA repair. 
One embodiment of the invention is directed to a phar 
maceutical composition for a subject in need of an elevation 
of intracellular NAD content. The pharmaceutical compo 
sition comprises a pro-NAD agent and a pharmaceutically 
acceptable carrier. The pro-NAD agent is present in the 
pharmaceutical composition at a concentration sufficient to 
elevate intracellular NAD in the subject. The pharmaceutical 
composition may be adapted for topical administration to the 
skin. Adaptation may included the inclusion of a pharma 
ceutically acceptable carrier Which is suitable for use in 
topical applications. 
The pro-NAD agents of the invention may comprise one 
or more compounds With the folloWing formula: 
Where R1 is a hydrogen or any chemical group that can be 
enZymatically or chemically removed to generate nicotinic 
acid folloWing administration to said subject. A chemical 
group is any chemical molecule such as, for example, any 
branched or unbranched (straight) alkane, alkene, or alkyne 
group. In a preferred embodiment, the chemical group is a 
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group such as an ester, that can be removed by an esterase 
following the administration of the pharmaceutical compo 
sition to the subject. Preferably, the esterase is an intracel 
lular esterase such that the chemical group is not removed 
until the pro-NAD agent is inside a cell. 
In a preferred embodiment, R1 is an unbranched or 
branched chain alkane, alkene or alkyne of 1 carbon to about 
30 carbon atoms, such as, for example betWeen about 14 and 
about 22 carbons. R1 may also contain one or more func 
tional groups. A functional group is an atom or group of 
atoms acting as a unit, that has replaced a hydrogen atom in 
a hydrocarbon molecule and Whose presence imparts char 
acteristic properties to a molecule. Examples of functional 
groups that can be used include thiol, alcohol, amine, 
carboxylic acid, onium, carboxylic anhydride, carboxylic 
ester, acyl halide, amide, nitrile, aldehyde, ketone, imines, 
ethers, sul?de, halide, nitro, nitroso, aZides, diaZo, and a 
combination of these groups. 
In a preferred embodiment, R1 may be a chemical group 
that changes the log PO/W of said pro-NAD agent to betWeen 
about 5 to about 20. 
In a preferred embodiment, the pro-NAD agent has a log 
PO/W range betWeen about 5 to about 20. More preferably, the 
pro-NAD agent has a log PO/W range betWeen about 10 to 
about 15. 
For example, the pro-NAD agent may be 
methylnicotinate, ethylnicotinate, butylnicotinate, 
hexylnicotinate, octylnicotinate, tetradecylnicotinate, octa 
decylnicotinate or a combination of these chemicals. A 
combination may be, for example, at least one chemical 
selected from the group consisting of methylnicotinate, 
ethylnicotinate, butylnicotinate, hexylnicotinate, octylnico 
tinate and at least one chemical selected from the group 
consisting of tetradecylnicotinate and octadecylnicotinate. 
Alternatively, the pro-NAD agent may comprise one or 
more compounds With the folloWing formula: 
Where R2 is a hydrogen or a chemical group that can be 
enZymatically or chemically removed to generate nicotina 
mide after the pharmaceutical composition is administered. 
For example, R2 may be a carboxylic acid containing an 
alkane, alkene or alkyne of about 1 to about 30 carbon 
atoms. Preferably, R2 is a carboxylic acid containing an 
alkane R group With betWeen 14 and 22 carbons. In addition 
R2 also contains one or more functional groups. The func 
tional group may be, for example, thiol, alcohol, amine, 
carboxylic acid, onium, carboxylic anhydride, carboxylic 
ester, acyl halide, amide, nitrile, aldehyde, ketone, imines, 
ethers, sul?de, halide, nitro, nitroso, aZides, or diaZo. Pre 
ferred functional groups include thiol, alcohol, amine, and 
carboxylic acid groups. R2 may also have more than one 
functional group. Further, R2 may be any chemical group 
that changes the log PO/W of said pro-NAD agent to betWeen 
about 5 to about 20. Preferably, the pro-NAD agent has a log 
PO/W range betWeen about 5 to about 20. More preferably, the 
pro-NAD agent has a log PO/W range betWeen about 10 to 
about 15. 
The pharmaceutical composition of the invention may 
have a pro-NAD agent concentration that is betWeen about 
0.001% to about 10% by Weight. Preferably, the pro-NAD 
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agent is betWeen about 0.01% and about 3% by Weight. The 
pharmaceutical composition may further comprise an 
optional agent such as, for example, antioxidants, 
sunscreens, vitamins, a pH stabiliZer, or a combination of 
these agents. 
It is understood that the pharmaceutical composition of 
the invention may be used for treating a subject. The subject 
is an animal. The animal may be a unicellular or a multi 
cellular animal such as, for example, a mammal. Further, the 
mammal may be a human. The subject may also be a 
cultured cell population, a cultured cell line, an egg, a sperm 
or a Zygote. 
Another embodiment of the invention is directed to a 
method for treating or for sloWing skin deterioration. In the 
method, a pharmaceutical composition of the invention may 
be administered to a subject to treat, sloW or reverse skin 
deterioration in the subject. Preferably, the method Will 
increase the skin cell intracellular NAD concentration by at 
least about 50% over an untreated subject. More preferably, 
the method Will increase the intracellular NAD concentra 
tion by an even greater amount such as, for example, by 
100% over an untreated subject. It is understood that skin 
cell in this application refers to ?broblasts and/or kerati 
nocytes. The administration may be applied topically, intra 
dermally or subcutaneously. Topical administration may be 
via dermal patch or sloW release mechanism to the layer of 
skin of the mammal. In addition, the administration may be 
oral or parenteral. 
Another embodiment of the invention is directed to a 
process for achieving transdermal delivery of a pro-NAD 
agent. In the process, an effective amount of a topical 
composition comprising an effective amount of one or more 
pro-NAD agent is applied to the skin of a subject. The 
pro-NAD agent used in this process may be any pro-NAD 
agent discussed in this application. 
Another embodiment of the invention is directed to a 
process for reducing the cytotoxic effects of DNA damage in 
the skin of a mammal by enhancing or elevating one or more 
skin cell intracellular proteins. The skin cells are the ?bro 
blasts and/or keratinocytes in the skin. The process com 
prises applying to a layer of skin of the mammal an effective 
amount of a pharmaceutical composition of the invention. 
The intracellular protein may be p53. Alternatively, the 
intracellular protein may be PARP-1, PARP-2, PARP-3, 
tankyrase, V-PARP and telomerase. 
Another embodiment of the invention is directed to a 
method for treating skin in order to inhibit skin deterioration 
due to UV exposure. In the method, a pharmaceutical 
composition of the invention is applied to the skin at a time 
sufficiently close to the time of UV exposure to inhibit 
UV-induced damage to the skin. The pharmaceutical com 
position may be applied before UV exposure. Alternatively, 
the pharmaceutical composition maybe applied after UV 
exposure. The time of application may be for example, less 
than 1 hour, less than 2 hour, less than 6 hour, less than 12 
hour or less than 1 day before UV exposure. Alternatively, 
the time of application may be, for example, less than 5 
minutes, less than 10 minutes, less than 20 minutes, less than 
1 hour, less than 2 hours, less than 6 hours, less than 12 
hours, less than 1 day, less than 2 days, or less than 5 days 
after UV exposure. 
Other embodiments and advantages of the invention are 
set forth, in part, in the description Which folloWs and, in 
part, Will be obvious from this description and understood by 
the skilled artisan practicing this invention. 
DESCRIPTION OF THE DRAWINGS 
FIG. 1 depicts a diagram of skin marking the location of 
the tWo major cell types present in skin, namely ?broblasts 









